Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L Acquires 4,820,959 Shares

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L bought 4,820,959 shares of the firm’s stock in a transaction on Friday, February 28th. The stock was purchased at an average price of $1.06 per share, for a total transaction of $5,110,216.54. Following the completion of the acquisition, the director now directly owns 58,846,780 shares in the company, valued at $62,377,586.80. The trade was a 8.92 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Standard BioTools Stock Up 5.0 %

NASDAQ:LAB traded up $0.05 on Tuesday, hitting $1.06. The stock had a trading volume of 2,879,143 shares, compared to its average volume of 2,149,665. The stock has a market cap of $394.59 million, a price-to-earnings ratio of -1.49 and a beta of 1.57. The company has a fifty day moving average price of $1.58 and a two-hundred day moving average price of $1.79. Standard BioTools Inc. has a 1-year low of $0.99 and a 1-year high of $3.04.

Hedge Funds Weigh In On Standard BioTools

Several large investors have recently made changes to their positions in LAB. Creative Planning acquired a new position in shares of Standard BioTools in the 3rd quarter worth approximately $39,000. Nisa Investment Advisors LLC lifted its holdings in shares of Standard BioTools by 433.8% in the 3rd quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company’s stock worth $35,000 after acquiring an additional 14,732 shares during the last quarter. Royce & Associates LP lifted its holdings in shares of Standard BioTools by 102.0% in the 3rd quarter. Royce & Associates LP now owns 614,552 shares of the company’s stock worth $1,186,000 after acquiring an additional 310,321 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Standard BioTools in the 3rd quarter worth approximately $101,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Standard BioTools by 188.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,445,083 shares of the company’s stock worth $4,719,000 after acquiring an additional 1,597,728 shares during the last quarter. 53.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, KeyCorp lowered shares of Standard BioTools from an “overweight” rating to a “sector weight” rating in a report on Thursday, February 27th.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.